# US 2004/0082075 A1 · Multi-step NMR for the identification and evaluation of biomolecule-compound interactions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082075 A1
- Document ID: US20040082075A1
- Status: Published application
- Kind: A1
- Application number: 10/280,899
- Filed: 2002-10-25
- Published: 2004-04-29
- Earliest claimed: 2002-10-25
- Inventors: Robert Powers
- Web page: https://patentgrep.com/patent/US20040082075A1

## CPC

- G01N 24/08: by using nuclear magnetic resonance (G01N24/12 takes precedence)
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- Y10T 436/24: Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Provided are methods of evaluating binding or a compound to a biomolecule. The methods utilize 1D NMR of the compound and 1D or 2D NMR of the biomolecule-compound mixture, along with 2D HSQC or TROSY methodology if a biomolecule-compound complex is formed. These methods are useful for evaluating biomolecule binding with more than one compound, e.g., a library of compounds, either individually or in mixtures. The methods are also useful for NMR evaluation of the effects of competition between a compound and a known binder such as an inhibitor of biomolecule activity.

## Claims

### Claim 1

A method of evaluating binding of a compound to a biomolecule, the method comprising
a. obtaining a 1D NMR spectra for the compound;
b. contacting the compound with the biomolecule to create a biomolecule-compound mixture;
c. evaluating whether the compound specifically binds to the biomolecule by
i. obtaining 1D or 2D NMR spectra of the biomolecule-compound mixture; and
ii. analyzing the data in step i. to determine whether the compound binds to the biomolecule to form a biomolecule-compound complex; and
d. if a biomolecule-compound complex is formed, further analyzing the biomolecule-compound complex by obtaining and evaluating additional NMR spectra for the biomolecule-compound complex using 2D HSQC or TROSY NMR methodology.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biomolecule is a polypeptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polypeptide is an enzyme.

### Claim 4 (depends on 2)

The method of claim 2, wherein the polypeptide is selected from the group consisting of a cytokine, a transcription factor, a structural protein, a viral protein, and a bacterial protein.

### Claim 5 (depends on 1)

The method of claim 1, wherein the biomolecule is a nucleic acid.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein more than one compound is in the biomolecule-compound mixture.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the spectra obtained in step c.i. is 1D NMR spectra.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, further comprising obtaining and evaluating biomolecule-compound interaction information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line width, peak height, NOE, a relaxation parameter, and/or a dynamic parameter.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the spectra obtained in step d. is 2D 1H-15N HSQC spectra.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the spectra obtained in step d. is 2D 1H-13C HSQC spectra.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the spectra obtained in step d. is 2D TROSY spectra.

### Claim 12 (depends on 11)

The method of claim 11, wherein the biomolecule is greater than 25 kDa.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, further comprising obtaining and evaluating 2D trNOE spectra of the biomolecule-compound complex.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein a binding site of the compound to the biomolecule is further defined by mapping amino acid residues exhibiting chemical shift perturbations onto a molecular surface of the biomolecule.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, further comprising 15N and/or 13C labeling of a specific residue type.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, further comprising a competition NMR experiment with a second compound.

### Claim 17 (depends on 16)

The method of claim 16, wherein the competition NMR experiment utilizes 1D NMR or 2D NMR.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein the second compound is a known binder of the biomolecule.

### Claim 19 (depends on 18)

The method of claim 18, wherein the competition NMR experiment involves evaluating 1D line-width changes of the compound upon addition of the biomolecule, then addition of the known binder followed by a further evaluation of 1D line-width changes of the compound.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the competition NMR experiment further comprises
evaluating the compound and/or biomolecule information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line-width, peak height, NOEs, a relaxation parameter and/or a dynamic parameter;
adding the known binder; then
further evaluating the compound and/or biomolecule information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line-width, peak height, NOEs, a relaxation parameter and/or a dynamic parameter.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the competition NMR experiment is performed after obtaining the 1D or 2D NMR spectra of step c.i.

### Claim 22 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the competition NMR experiment is performed after obtaining the 2D 1H-15N HSQC or TROSY spectra of step d.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The method of any one of claims 17-22, wherein the second compound is an inhibitor of a function of the biomolecule.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, further comprising analyzing the effect of the compound on an activity of the biomolecule.

### Claim 25 (depends on 24)

The method of claim 24, wherein the effect analyzed is inhibition of the activity of the biomolecule.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, further comprising analyzing the structure of a biomolecule-compound complex.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, further comprising
(A) preparing a library of structural analogs of a compound that forms a biomolecule-compound complex with the biomolecule; and
(B) evaluating the analogs for binding to the biomolecule or affecting activity of the biomolecule.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein more than one biomolecule-compound mixture is evaluated.

### Claim 29

A method of determining binding of compounds in a library to a biomolecule, the method comprising
a. obtaining a 1D NMR spectra for each compound in the library;
b. contacting compounds in the library with the biomolecule to create multiple biomolecule-compound mixtures;
c. evaluating whether each of the compounds specifically binds to the biomolecule by
i. obtaining 1D or 2D NMR spectra of each biomolecule-compound mixture; and
ii. analyzing the data in step i. to identify compounds that bind to the biomolecule to form a biomolecule-compound complex; and
d. further analyzing each biomolecule-compound complex by obtaining and evaluating additional NMR spectra for the biomolecule-compound complex using 2D HSQC or TROSY NMR methodology.

### Claim 30 (depends on 29)

The method of claim 29, wherein the biomolecule is a polypeptide.

### Claim 31 (depends on 30)

The method of claim 30, wherein the polypeptide is an enzyme.

### Claim 32 (depends on 30)

The method of claim 30, wherein the polypeptide is selected from the group consisting of a cytokine, a transcription factor, a structural protein, a viral protein, and a bacterial protein.

### Claim 33 (depends on 29)

The method of claim 29, wherein the biomolecule is a nucleic acid.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The method of any one of claims 29-33, wherein more than one compound is in the biomolecule-compound mixture.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

The method of any one of claims 29-34, wherein the compounds of step b. do not include compounds in the library that have one or more undesirable characteristic identified by 1D NMR.

### Claim 36 (depends on 35)

The method of claim 35, wherein the one or more undesirable 1D NMR characteristic is selected from the group consisting of low solubility, compound instability, inaccurate structure, tendency to form aggregates, tendency to form micelle-like structures, and tendency to denature the biomolecule.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 29-36, wherein the spectra obtained in step c.i. is 1D NMR spectra.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 29-37, further comprising obtaining and evaluating biomolecule-compound interaction information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line-width, peak height, NOEs, a relaxation parameter and/or a dynamic parameter.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 29-38, wherein the analysis of step d. is not performed with biomolecule-compound complexes that have one or more undesirable biomolecule, compound, and/or biomolecule-compound complex NMR characteristic.

### Claim 40 (depends on 39)

The method of claim 39, wherein the undesirable characteristic is selected from the group consisting of low solubility, tendency to form aggregates, compound instability, inaccurate structure, tendency to form micelle-like structures, and tendency to denature the biomolecule.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 29-40, wherein the information in step c.ii. is obtained from 1D STD.

### Claim 42 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 29-41, wherein the spectra obtained in step d. is 2D 1H-15N HSQC spectra.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 29-41, wherein the spectra obtained in step d. is 2D 1H-13C HSQC spectra.

### Claim 44 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 29-41, wherein the spectra obtained in step d. is 2D TROSY.

### Claim 45 (depends on 44)

The method of claim 44, wherein the biomolecule is >25 kDa.

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 29-45, further comprising obtaining and evaluating 2D trNOE spectra of the biomolecule-compound complex.

### Claim 47 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 29-46, wherein a binding site of the compound to the biomolecule is further defined by mapping amino acid residues exhibiting chemical shift perturbations onto a molecular surface of the biomolecule.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 29-47, further comprising 15N and/or 13C labeling of a specific residue type.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 29-48, further comprising a competition NMR experiment with a second compound.

### Claim 50 (depends on 49)

The method of claim 49, wherein the competition NMR experiment utilizes 1D NMR or 2D NMR.

### Claim 51 (depends on 49, 50)

The method of claim 49 or 50, wherein the second compound is a known binder of the biomolecule.

### Claim 52 (depends on 51)

The method of claim 51, wherein the competition NMR experiment involves evaluating 1D line-width changes of the compound upon addition of the biomolecule, then addition of the known binder followed by a further evaluation of 1D line-width changes of the compound.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the competition NMR experiment further comprises
evaluating the compound and/or biomolecule information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line-width, peak height, NOEs, a relaxation parameter and/or a dynamic parameter;
adding the known binder; then
further evaluating the compound and/or biomolecule information using a technique selected from the group consisting of 1D STD, WaterLOGSY, a transferred NOE, a relaxation measurement, a diffusion-edited measurement, NOE pumping, and a method that observes changes in chemical shifts, line-width, peak height, NOEs, a relaxation parameter and/or a dynamic parameter.

### Claim 54 (depends on 49, 50, 51, 52)

The method of any one of claims 49-52, wherein the competition NMR experiment is performed after obtaining the 1D or 2D NMR spectra of step c.i.

### Claim 55 (depends on 49, 50, 51, 52)

The method of any one of claims 49-52, wherein the competition NMR experiment is performed after obtaining the 2D 1H-15N HSQC or TROSY spectra of step d.

### Claim 56 (depends on 51, 52, 53, 54, 55)

The method of any one of claims 51-55, wherein the second compound is an inhibitor of a function of the biomolecule.

### Claim 57 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 29-56, further comprising analyzing the effect of the compound on an activity of the biomolecule.

### Claim 58 (depends on 57)

The method of claim 57, wherein the effect analyzed is inhibition of the activity of the biomolecule.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, further comprising analyzing the structure of a biomolecule-compound complex.

### Claim 60 (depends on 59)

The method of any one of claims 59, wherein the structure analyzed is a three-dimensional structure.

### Claim 61 (depends on 60)

The method of claim 60, wherein the three-dimensional structure is analyzed using a method selected from the group consisting of molecular modeling, NMR spectroscopy, and X-ray crystallography.

### Claim 62 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 29-61, further comprising
(A) preparing a second library, the second library comprising structural analogs of a compound that forms a biomolecule-compound complex with the biomolecule; and
(B) evaluating the analogs for binding to the biomolecule or affecting activity of the biomolecule.

### Claim 63 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A process for selecting a compound that binds to a biomolecule, the process comprising
I. obtaining a library of compounds;
II. determining binding of the compounds to the biomolecule using the method of any one of claims 29-62;
III. preparing a second library, the second library comprising structural analog compounds of a compound that forms a biomolecule-compound complex with the biomolecule;
IV. evaluating the analog compounds for desirable binding characteristics or an ability to affect an activity of the biomolecule; and
V. selecting an analog compound evaluated in IV. that has desirable binding characteristics or affects an activity of the biomolecule.

### Claim 64 (depends on 63)

The process of claim 63, wherein the biomolecule is a polypeptide.

### Claim 65 (depends on 64)

The process of claim 64, wherein the polypeptide is an enzyme.

### Claim 66 (depends on 64)

The process of claim 64, wherein the polypeptide is selected from the group consisting of a cytokine, a transcription factor, a structural protein, a viral protein, and a bacterial protein.

### Claim 67 (depends on 63)

The process of claim 63, wherein the biomolecule is a nucleic acid.

### Claim 68 (depends on 63, 64, 65, 66, 67)

The process of any one of claims 63-67, wherein the selected analog compound is an inhibitor of an activity of the biomolecule.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A compound that binds to a biomolecule, the compound selected using the method of any one of claims 1-62 or the process of any one of claims 63-68.
